Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 6/20 | 0.43 |
| ▸ | MC5R | P33032 | 1/20 | 0.43 |
| ▸ | MC3R | P41968 | 1/20 | 0.43 |
| ▸ | MC1R | Q01726 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | REN | P00797 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6047836 | 0.96 | MC4R (0.42) | MC4RMC5RMC3RMC1RMTNR1A | |
| SCHEMBL6047798 | 0.93 | MC4R (0.39) | MC4RMC5RMC3RMC1RMTNR1A | |
| SCHEMBL6047782 | 0.89 | MTNR1A (0.39) | MTNR1AMTNR1B | |
| SCHEMBL4696937 | 0.88 | MTNR1A (0.38) | MTNR1AMTNR1B | |
| SCHEMBL6047801 | 0.86 | MTNR1A (0.37) | MTNR1AMTNR1BKCNH2 | |
| SCHEMBL6047816 | 0.85 | MTNR1A (0.37) | MTNR1AMTNR1BKCNH2 | |
| SCHEMBL6047818 | 0.81 | MC4R (0.48) | MC4RMC5RMC3RMC1RMTNR1A | |
| SCHEMBL6047820 | 0.80 | MC4R (0.46) | MC4RMC5RMC3RMC1RMTNR1A | |
| SCHEMBL6047867 | 0.80 | MC4R (0.46) | MC4RMC5RMC3RMC1RMTNR1A | |
| SCHEMBL6047763 | 0.79 | CXCR3 (0.38) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148805-A1 | Opthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME CORP. | 2006-07-06 | — | — | US | claimed |
| US-20060148805-A1 | Opthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME CORP. | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148805-A1 | Opthalmic compositions for treating ocular hypertension | KCNH2, KCNH3, KCNN1 | MC4R 1970/4885MC5R 666/4885MC3R 1367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.